The U.S. Supreme Court’s landmark ruling that DNA segments are a product of nature and hence not patent-eligible has worldwide significance because it settles the controversial issue of patenting human genes in the one jurisdiction where it has come to matter the most. Though the ruling said that the mere act of isolating genes “is … Continue reading Editorial: BRCA genes – Patent justice
Editorial: When commerce rules the roost
Awareness about genetic testing to know if a woman with a family history of breast cancer and ovarian cancer carries certain deleterious mutations in the BRCA1 and BRCA2 genes has surely increased following Angelina Jolie’s recent revelation of her bilateral mastectomy. In the process, she has turned the spotlight on a high-voltage patent case in … Continue reading Editorial: When commerce rules the roost
BRCA gene case: will the court take the middle ground?
The U.S. Supreme Court is currently hearing a case on the validity of the isolated DNA and cDNA patents filed on BRCA1 and BRCA2 human genes used for diagnosing breast and ovarian cancers. The Association for Molecular Pathology has petitioned the Supreme Court to invalidate the patents held jointly by the Utah-based Myriad Genetics and … Continue reading BRCA gene case: will the court take the middle ground?
‘Not all BRAC1, BRAC2 mutations result in breast cancer’
“Genetic test for BRCA1/2 is not recommended as a screening test,” said Dr. Vani Parmar, Associate Professor, Department of Surgical Oncology at Tata Memorial Hospital, Mumbai. “We don’t recommend it for individuals who do not have a family history or if they do not already have breast cancer.” However, genetic testing would be recommended for … Continue reading ‘Not all BRAC1, BRAC2 mutations result in breast cancer’